Tnfrsf4 antibody treatment reduced L-Gr-1+ cells in the peripheral blood and significantly prolonged survival of CML mice with 60% of mice surviving long-term (Figure 7, D and E). The gene discussed is TNFRSF4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.